What is Servatus?
Founded in 2012 and headquartered in Coolum Beach, Queensland, Australia, Servatus is a biotechnology firm dedicated to pioneering microbial-based drug development. The company is actively advancing several prospective treatments through human clinical trials, aiming to provide effective alternatives for debilitating autoimmune, inflammatory, gastrointestinal, and dermatological conditions. Servatus's focus on microbiome science positions it within a rapidly growing segment of the pharmaceutical industry.
How much funding has Servatus raised?
Servatus has raised a total of $7.5M across 1 funding round:
Unspecified
$7.5M
Unspecified (2021): $7.5M, investors not publicly disclosed
What's next for Servatus?
The recent major strategic investment signifies a critical juncture for Servatus, likely enabling the company to accelerate its clinical trial pipeline and scale its research and development operations. This substantial backing suggests confidence from investors in Servatus's innovative approach to treating complex diseases. The company is poised to further its mission of delivering advanced therapeutic options to patients worldwide, potentially marking a significant step towards commercialization and broader market impact.
See full Servatus company page
